New Generation of Technologies Changing Treatment Paradigms

Moderator: Brian Meshkin, Managing Partner, Profound Ventures
Sally Allain, MBA, Head, JLABS @ Washington, DC, Johnson & Johnson Innovation
Joshua Barney, Member, Barrington Angels
Petr Sramek, Co-Founder, Chairman & Managing Partner, LongevityTech.fund

This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:

  • Current areas of interest
  • Current challenges in this ecosystem – Navigating the competitive landscape
  • Commonly observed red flags
  • Successful deals

Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

Speaker Bios

Sally Allain, MBA, Head, JLABS @ Washington, DC, Johnson & Johnson Innovation
As Head of JLABS @ Washington, DC, Sally sets the strategic direction and oversees all operational activities for JLABS in the greater Washington metro region, including Maryland and Virginia. In this role, Sally is responsible for the process of evaluating and selecting a strong portfolio of innovators for JLABS @ Washington, DC, and building strategic partnerships with corporate, academic, government and industry organizations that aim to strengthen the region’s life sciences innovation network. Sally joined JLABS after serving as Senior Director, Strategy & Operations on the Global External Innovation team at Johnson & Johnson, where she supported portfolio management and reporting and strategic business development efforts across the organization. Prior, Sally was with Janssen R&D, Immunology, where she managed a team in research operations and alliance management for the early discovery to early development portfolio. Sally understands well the needs of healthcare entrepreneurs, having launched her research career at a San-Diego based biotech startup and then working internationally for a UK-based governmental economic development agency creating early-stage biotech and academic collaborative programs aimed at accelerating the development of products to address the needs of patients and consumers. Sally received her MBA from the University of California Berkeley, Haas School of Business, where she was recognized by ‘Poets and Quants’ as one of the ‘Top 50’ EMBA students across US & International Programs in 2016; a Master of Science Degree in Microbiology / Immunology from Virginia Tech; and a Bachelor of Science Degree in Biology from Virginia Tech.

Joshua Barney, Member, Barrington Angels
Josh was a co-founder and executive of several startup companies. He now invests in technology and biotech startups through angel funds including SISUFunds and Barrington Angels. He is the managing partner of Barney & Karamanis, LLP, JS Barney and Associates, Ltd. and SBRA.LAW. He served as general counsel and financial advisor for the U. S. operations of several foreign corporations including LSIS (formerly LG Corporation), Kawasaki Trading and Kia Motors. He previously owned a law firm in Beverly Hills. He holds BS degrees in marketing and finance from CSU Chico, JD from UC Davis, and an LLM from Columbia University, NY. Barney is licensed to practice law in California and Illinois.

Brian Meshkin, Managing Partner, Profound Ventures (Moderator)
Brian Meshkin’s social entrepreneurship began as an award-winning youth activist. At 13 years of age following the tragic death of a friend in front of his home, he led the lobbying effort to pass the nation’s first bicycle helmet law for children. Following this tragedy, he worked with the National Safe Kids Campaign (now called Safe Kids Worldwide), along with many others to advocate for similar efforts across the nation. Today, Brian has become an award-winning entrepreneur and technology executive. He has been recognized nationally and locally for his achievements, having founded and led some of the fastest growing technology companies in North America – ranked in the Deloitte Technology Fast 500 and the Inc. 500. The Baltimore Sun selected Brian as one of five “Earthly Angels” for his positive impact. He was chosen as the 2016 Emerging Technology Company CEO of the Year by the OC Tech Alliance/OCTANe, as a 2016 Excellence in Entrepreneurship Winner from the OC Business Journal, and a two-time finalist for the EY Entrepreneur of the Year Award. Previously, Brian was a Team Leader at the e.Lilly venture fund, a division of Eli Lilly, former manager of digital health for Johnson & Johnson’s largest product, and helped direct marketing efforts for Prometheus Laboratories. As a pioneer in big data and precision medicine, he founded Proove Biosciences which created the world’s largest clinical-genetics database of over 150,000 pain patients. Proove’s R&D efforts involved leading academic centers across North America and won research awards from leading medical societies. In 2010, Brian became the youngest ever-elected school board member for one of the nation’s leading school systems. He is a graduate of the University of Maryland at College Park.

Petr Sramek, Co-Founder, Chairman & Managing Partner, LongevityTech.fund
Petr Sramek is a Czech visionary, a serial entrepreneur of over 30 years. Petr helps innovative startups in the field of Artificial Intelligence and Longevity technology to grow into confident companies with global ambitions. Petr is a founder of LongevityTech.fund, Entrepreneur in Residence at Singularity University, CEO of Whytics, co-founder of the Platform on Artificial Intelligence at the Confederation of Industry, member of Peter Diamandis´s organization Abundance 360, Lifeboat Foundation, and a Senator for Czech Republic in the World Business Angels Investment Forum (WBAF). Petr is a founder of the AI Awards project in a co-operation with Economia – a leading business media publishing house. Petr has been featured in the group of 28 AI leaders in the flagship World Intellectual Property Organization study.